Patents by Inventor Naveed Shams
Naveed Shams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240000763Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.Type: ApplicationFiled: September 11, 2023Publication date: January 4, 2024Applicant: Santen Pharmaceutical Co., Ltd.Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
-
Patent number: 11793798Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.Type: GrantFiled: November 8, 2021Date of Patent: October 24, 2023Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
-
Publication number: 20230277515Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.Type: ApplicationFiled: May 10, 2023Publication date: September 7, 2023Applicant: Santen Pharmaceutical Co., Ltd.Inventors: Hisashi Kawata, Noriko Kawabata, Naveed Shams
-
Patent number: 11666563Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.Type: GrantFiled: December 27, 2018Date of Patent: June 6, 2023Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Hisashi Kawata, Noriko Kawabata, Naveed Shams
-
Publication number: 20220054466Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.Type: ApplicationFiled: November 8, 2021Publication date: February 24, 2022Applicant: Santen Pharmaceutical Co., Ltd.Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi KAWATA, Noriko KAWABATA
-
Patent number: 11197849Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.Type: GrantFiled: May 29, 2020Date of Patent: December 14, 2021Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
-
Publication number: 20200345713Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.Type: ApplicationFiled: December 27, 2018Publication date: November 5, 2020Applicant: Santen Pharmaceutical Co., Ltd.Inventors: Hisashi Kawata, Noriko Kawabata, Naveed Shams
-
Publication number: 20200289483Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.Type: ApplicationFiled: May 29, 2020Publication date: September 17, 2020Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi KAWATA, Noriko KAWABATA
-
Patent number: 10702511Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.Type: GrantFiled: December 6, 2018Date of Patent: July 7, 2020Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
-
Publication number: 20190105310Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.Type: ApplicationFiled: December 6, 2018Publication date: April 11, 2019Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi Kawata, Noriko Kawabata
-
Patent number: 10179127Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.Type: GrantFiled: February 13, 2018Date of Patent: January 15, 2019Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
-
Publication number: 20180169079Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.Type: ApplicationFiled: February 13, 2018Publication date: June 21, 2018Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi KAWATA, Noriko KAWABATA
-
Patent number: 9943510Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.Type: GrantFiled: July 18, 2016Date of Patent: April 17, 2018Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
-
Publication number: 20160324838Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.Type: ApplicationFiled: July 18, 2016Publication date: November 10, 2016Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi KAWATA, Noriko KAWABATA
-
Patent number: 9415038Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.Type: GrantFiled: January 8, 2015Date of Patent: August 16, 2016Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
-
Publication number: 20150196541Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.Type: ApplicationFiled: January 8, 2015Publication date: July 16, 2015Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
-
Patent number: 8911426Abstract: An implantable drug delivery device that uses multiple reservoir elements to contain and release doses of active pharmaceutical ingredients. The device includes a first shell element, which has a first enclosed cavity volume and forms a low-permeability barrier. The first shell element is configured to absorb light irradiation from a laser source, the laser irradiation causing a breach in the first shell element. A first active pharmaceutical ingredient is contained in the first enclosed cavity volume and is released when the first shell element is breached. The device also includes a second shell element, which has a second enclosed cavity volume and also forms a low-permeability barrier. A second active pharmaceutical ingredient is contained in the second enclosed cavity volume. The device also includes an envelope element containing the first and second shell elements.Type: GrantFiled: February 8, 2011Date of Patent: December 16, 2014Assignee: On Demand Therapeutics, Inc.Inventors: Jonathan Robert Coppeta, Kenneth N. Horne, John T. Santini, Jr., John A. Scholl, Gregory J. R. Spooner, Cynthia L. Stevenson, Naveed Shams, Andrew Poutiatine
-
Patent number: 8470792Abstract: Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Such compositions and methods further involve siRNA capable of selectively targeting angiogenic VEGF isoforms while selectively sparing anti-angiogenic isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.Type: GrantFiled: December 4, 2009Date of Patent: June 25, 2013Assignee: Opko Pharmaceuticals, LLC.Inventors: Phillip Frost, Nadine Dejneka, Ottrina S. Bond, Naveed Shams
-
Publication number: 20120035528Abstract: An implantable drug delivery device that uses multiple reservoir elements to contain and release doses of active pharmaceutical ingredients. The device includes a first shell element, which has a first enclosed cavity volume and forms a low-permeability barrier. The first shell element is configured to absorb light irradiation from a laser source, the laser irradiation causing a breach in the first shell element. A first active pharmaceutical ingredient is contained in the first enclosed cavity volume and is released when the first shell element is breached. The device also includes a second shell element, which has a second enclosed cavity volume and also forms a low-permeability barrier. A second active pharmaceutical ingredient is contained in the second enclosed cavity volume. The device also includes an envelope element containing the first and second shell elements.Type: ApplicationFiled: February 8, 2011Publication date: February 9, 2012Applicants: MicroCHIPS, Inc., On Demand Therapeutics, Inc.Inventors: Jonathan R. Coppeta, Kenneth N. Horne, John T. Santini, JR., John A. Scholl, Gregory J.R. Spooner, Cynthia L. Stevenson, Naveed Shams, Andrew Poutiatine
-
Patent number: RE48183Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.Type: GrantFiled: August 28, 2018Date of Patent: September 1, 2020Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata